Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences

European Journal of Haematology

Volumn 72, Issue 3, 2004, Pages 172-180

  Gulbrandsen, Nina ^a   Hjermstad, Marianne J ^b   Wisløff, Finn ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

High dose chemotherapy; Multiple myeloma; Quality of life; Reference population; Stem cell support

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; MELPHALAN; PREDNISONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE MYELOMA; NORWAY; PAIN; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SCORING SYSTEM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TUMOR DIAGNOSIS;

EID: 1342322717     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0902-4441.2003.00195.x     Document Type: Article

References (20)

1. CELLA D, BULLINGER M, SCOTT C, BAROFSKY I. Clinical Significance Consensus Meeting Group. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc 2002;77:384-392.
2. HJORTH M, WESTIN J, DAHL IM, et al. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Ann Intern Med 1996;124:212-222.
3. LENHOFF S, HJORTH M, HOLMBERG E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000;95:7-11.
4. WISLØFF F, EIKA S, HIPPE E, HJORTH, M, HOLMBERG E, KAASA S, PALVA I, WESTIN J. Measurement of health-related quality of life in multiple myeloma. Br J Haematol 1996;92:604-613.
5. GULBRANDSEN N, WISLOFF F, BRINCH L, et al. The Nordic Myeloma Study Group. Health-related quality of life in myeloma patients receiving high dose chemotherapy with autologous blood stem cell support. Med Oncol 2001;18:65-77.
6. HJERMSTAD MJ, FAYERS PM, BJORDAL K, KAASA S. Health related quality of life in the general population assessed by the EORTC Core Quality of Life Questionnaire - the EORTC QLQ-C30 (+ 3). J Clin Oncol 1998;16:1188-1196.
7. OSOBA D, RODRIGUES G, MYLES J, ZEE B, PATER J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144.
8. AARONSON NK, AHMEDZAI S, BERGMAN B, BULLINGER M, CULL A, DUEZ NJ, FILIBERTI A, FLECHTNER H, FLEISCHMAN SB, de HAES JC. The European Organization for Research and Treatment of Cancer QLQ C-30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
9. KAASA S, BJORDAL K, AARONSON N, MOUM T, WIST E, HAGEN S, KVIKSTAD A. The EORTC Core Quality of Life Questionnaire (QLQ C-30): validity and reliability when analyzed with patients treated with palliative radiotherapy. Eur J Cancer 1995;31A:2260-2263.
10. HJERMSTAD MJ, FOSSA SD, BJORDAL K, KAASA S. Test/retest study of the European Organization for Research and Treatment of Cancer core quality of life questionnaire. J Clin Oncol 1996;13:1249-1254.
11. FAYERS P, AARONSON N, BJORDAL K, GROENVOLD M, CURRAN D, BOTTOMLEY A, ON BEHALF OF THE EORTC QUALITY OF LIFE GROUP. EORTC QLQ C-30 Scoring Manual. 3rd edn. Brussels: European Organisation for Research and Treatment of Cancer, 2001.
12. HJERMSTAD MJ, FAYERS PM, BJORDAL K, KAASA S. Using reference data on quality of life - the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+ 3). Eur J Cancer 1998;34:1381-1389.
13. FAYERS PM, MACHIN D. Quality of Life. Assessment, Analysis and Interpretation. John Wiley & Sons, 2000:338-343.
14. COHEN J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press, 1977:8.
15. MICHELSON H, BOLUND C, NILSSON B, BRANDBERG Y. Health-related quality of life measured by the EORTC QLQ-C30. Reference values from a large sample of the Swedish population. Acta Oncol 2000;39:477-484.
16. BRAZIER JE, HARPER R, JONES NM, O'CATHAIN A, THOMAS KJ, USHERWOOD T, WESTLAKE L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-164.
17. JENKINSON C, COULTER A, WRIGHT L. Short form 36 (SF36) health survey questionnaire: Normative data for adults of working age. BMJ 1993;306:1437-1440.
18. GARRAT AM, RUTA DA, ABDALLA MI, BUCKINGHAM JK, RUSSELL IT. The SF-36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993;306:1440-1444.
19. SPRANGERS MA, MOINPOUR CM, MOYNIHAN TJ, PATRICK DL, REVICKI DA. Clinical Significance Consensus Meeting Group. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc 2002;77:61-71.
20. CELLA D, HAHN EA, DINEEN K. Meaningful change in cancer-specific quality of life scores. Differences between improvement and worsening. Qual Life Res 2002;11:207-221.